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Mitochondrial metabolic alterations in cancer cells and related therapeutic targets 
 
Mitochondria have been regarded as the power generators of cells. Despite cancer cells have 
higher demand of energy than non-transformed cells, since Otto H. Warburg discovered that 
cancer cells have high glycolytic flux also in the presence of oxygen, the study of mitochondria 
metabolism and functions in cancer has been neglected for long time. Indeed, it was 
erroneously supposed that cancer cells have defective mitochondria, unable to meet the energy 
demands of transformed cells. Far from being defective, in the last twenty years it has become 
clear that mitochondria are often the drivers of the malignant phenotype.  
Indeed, many tumors exploit also mitochondria-related pathways, such as tricarboxylic acid 
(TCA) cycle and the oxidative phosphorylation (OXPHOS), fueled by the fatty acid β-
oxidation (FAO) and the glutaminolysis, to produce ATP and building blocks. Mitochondrial 
reactive oxygen species (ROS), i.e. physiological side-products of OXPHOS, are finely tuned 
in cancer cells, where they can act as signaling molecules, stimulating pro-proliferative, anti-
apoptotic and pro-invasive pathways. A controlled balance of mitochondria dynamics is also 
critical to support an accelerated cell proliferation and migration. Since higher is the cell 
metabolic plasticity, higher is the ability to adapt to unfavorable conditions - such as nutrient 
shortage, hypoxia, oxidative stress induced by radiotherapy or chemotherapy, cells with a high 
plasticity in mitochondria functions are the most favored to survive to stressors, generating 
aggressive and potentially therapies-resistant clones. This Special Issue is focused on the latest 
discoveries on the mitochondrial metabolism related to cancer develop, progression and 
resistance. 
 
The physiological or pathological activation of specific mitochondrial enzymes have been 
related to oncogenic properties. For instance, succinate dehydrogenase (SDH) has emerged as 
a key enzyme in tumors, since it consumes succinate that promotes cell proliferation and 
migration. The loss of function of SDH, due to inactivating mutations, down-regulation of 
mRNA levels by specific miRNAs, dephosphorylation and/or deacetylation, inhibition of 
enzymatic activity by itaconate or by the mitochondrial chaperon Necrosis Factor Receptor-
Associated Protein (TRAP1), increases the level of succinate that inhibits several α-
ketoglutarate-dependent histone demethylase (α-kGDDs), producing a wide epigenetic 
reprogramming, activates several glycolytic enzymes via succinylation, turns off the 
mitochondrial metabolism, induces epithelial-mesenchimal transition (EMT) and 
angiogenesis. The possibility of detecting SDH in tissues and succinate in biological fluids, 
and of modulating SDH activity with several FDA-approved agents, paves the way to the 
identification of new biomarkers of tumor progression and to the use of mitochondrial-targeting 
treatments as new anti-cancer approaches [Dalla Pozza/Donadelli]. Very similarly to SDH, the 
loss of fumarate hydratase (FH) is a pro-oncogenic factor: the consequent increase in fumarate 
reduces the efficiency of mitochondrial OXPHOS, promotes cell proliferation, EMT and 
angiogenesis via the succinylation-dependent activation of pro-oncogenic factors and/or the 
inhibition of α-kGDDs. Of note, both the loss of SDH and FH are considered early events in 
the transformation cascade, pointing out that an alteration of the physiological mitochondrial 
metabolism may act as an oncogenic trigger [Schmidt/Frezza]. By contrast, a third metabolite 
of TCA, α-kG, acts as a potential onco-suppressor: contrarily to succinate and fumarate, it 
activates α-kGDDs promoting opposite epigenetic reprogramming. Moreover, α-kG activates 
the prolyl hydroxylases responsible for the stabilization of collagen matrix and the degradation 
of Hypoxia Inducible factor-1α (HIF-1α) and Nuclear Factor-kB (NF-kB), and acts as a ROS 
scavenger, contrasting several pro-proliferative and pro-invasive pathways [Abla/Porcelli]. 
Consistently, α-kG supplementation has been regarded as an anti-cancer strategy. On the other 
hand, by fueling the TCA, α-kG supplementation has the potential threaten to increase 
succinate and fumarate. Only the exact knowledge of the relative activities of SDH, FH and 
isocitrate dehydrogenase in a specific tumor can orient towards the use of TCA inhibitors or 
stimulators in order to achieve anti-tumor effects. 
Also glutamine is at the same time an anaplerotic metabolite of TCA, a source of carbon 
building block in proliferating cells and a signaling molecule, that increases the activity of 
mTOR, c-myc and c-jun oncogenic pathways, by transcriptional and post-translational 
mechanisms. Consistently, the down-regulation of glutaminase is often associated to reduced 
proliferation and migration of cancer cells. For this reason, glutaminase inhbitors have been 
widely explored as anti-proliferative strategy, and look particularly promising against 
glutamine-addicted tumors [Mates/Mazurek].  
Not only changes in mitochondrial enzymes, but also in co-factors synthesized de novo in 
mitochondria have an impact on tumor progression. For instance, lipoic acid, the cofactor of 
pyruvate dehydrogenase and α-kG dehydrogenase complexes, and coenzyme Q10, the electron 
shuttle between complex I and III, are strong anti-oxidant metabolites. Thanks to the ROS 
scavenging, they prevent the pro-proliferative and invasive phenotype induced by 
mitochondrial ROS. Both products, in combination with chemotherapy, have increased the 
overall survival of patients with metastatic cancers, suggesting that stimulating mitochondrial 
metabolism and buffering ROS are adequate strategies to prevent cell proliferation and 
migration in vivo [Thapa/Dallmann]. 
On the other hand, a high inter-patients and intra-tumor variability often characterize 
mitochondrial metabolism, making difficult designing a comprehensive picture of the 
reprogramming in mitochondria metabolism occurring in tumors. For instance, in non small 
cell lung cancer, the acetyl-coenzyme A entering the TCA cycle is generated from glucose in 
well-oxygenated areas and from fatty acids, lactate or amino-acids in the less-oxygenated areas 
of the same tumor. Curiously, glutamine, which is used by several tumors as fuel of 
mitochondrial metabolism, has a minor role in non small cell lung cancer in vivo, although it 
is effectively consumed in vitro [Maiem/Munoz-Pinedo]. This example highlights the need of 
a personalized mapping of mitochondrial metabolism in each patient, if we would like to pursue 
the goal of identifying the prevalent metabolic fluxes and the most suitable mitochondrial-
targeting agents in each patient. The plasticity of mitochondria metabolism also characterizes 
the tumor progression in the same patient, and is consequent to the progressive accumulation 
of mutations. For instance, while normal colon epithelial cells rely on the aerobic oxidation of 
glucose, c-myc amplification and/or KRAS mutations – two early events during epithelium 
transformation - shifts this scenario towards a glycolytic and glutaminolytic-dependent 
metabolism. If this is the predominant trait or primary colon cancers, metastatic cells further 
reprogram their metabolism, depending on the oxygen levels of the secondary localizations. 
Therefore, the use of metabolic modifiers targeting mitochondria, as adjuvant agents of 
chemotherapy and targeted-therapies, may produce paradoxically opposite effects, depending 
on tumor stage and site [La Vecchia/Sebastian]. 
The ever changing conditions of tumor microenvironment (TME) have an important role in 
training mitochondria of cancer cells to rapidly reprogram their metabolisms. The paradigmatic 
symbiosis between lactate- and glutamine-producing cancer associated fibroblasts (CAFs) and 
lactate-fueled tumor cells is one example on how mitochondria of cancer cells may obtain ATP 
by enhancing the enter of lactate and glutamine carbons, abundant in hypoxic TME, in the 
TCA/OXPHOS fluxes. Similarly, breast cancer cells trigger the lipolysis of stromal adipocytes 
and obtain energy by the oxidation of the released fatty acids. Of note, also mitochondrial DNA 
can be transferred by CAFs to cancer cells, via extracellular vesicles: this is another intriguing 
mechanism by which stromal cells increase the efficiency of mitochondrial metabolism, 
promoting cell proliferation, migration and EMT [Bacci/Chiarugi]. The bidirectional interplay 
between mitochondrial metabolites of immune-infiltrating cells and cancer cells also tips the 
balance between immune-evasion and immune-eradication of the tumor. On the one hand, an 
acute release of mitochondrial danger-associated molecular pattern (mtDAMP) molecules, 
such as mitochondrial ROS, DNA, ATP and cardiolipin, from cancer cells promote their 
immunogenic death by recruiting dendritic cells, inducing tumor cell phagocytosis, activating 
anti-tumor CD8+ T-cytotoxic lymphocytes. In advanced stages, however, the prolonged release 
of mtDAMPs, the depletion of aminoacids essential for lymphocyte proliferation as arginine 
and glutamine, the release of succinate, fumarate and itaconate, that favor the M2-polarization 
of tumor associated macrophages (TAMs), lead to the functional exhaustion of immune-
infiltrating cells. Increasing or inhibiting the mitochondrial metabolism may thus produce 
completely opposite effects on tumor immune-surveillance [Kopecka/Riganti]. The reciprocal 
influences between cancer cells, CAFs, adipocytes, immune-infiltrating cells, endothelial cells 
make extremely difficult a precise understanding of which compartment is the mainly affected 
by mitochondria-targeting agent. For instance, metformin, that inhibits mitochondrial complex 
I, acts on different components of TME. The anti-cancer effect of this drug must be considered 
the sum of the direct inhibition of tumor OXPHOS, and several indirect events, e.g. the 
inhibition of neo-angiogenic properties in endothelial cells, the inhibition of NF-kB-dependent 
inflammatory signals from CAFs, the prevailing M1-polarization of TAMs, the enhancement 
of cytotoxic properties of infiltrating lymphocytes [Kurelac/Gasparre].  
The existence of a continuous metabolic reprogramming during the evolution of the same 
tumor and/or within the same tumor, due to the complex interactions with TME, requires new 
in vitro systems and assays to study tumor metabolism in a real time fashion and in the closest 
way to mimic the tumor-TME network existing in vivo. To this aim, organoids and organotypic 
3D-cultures represent important technological advancements that allow the study of 
mitochondrial metabolism and functions in live tumor cells, surrounded by a TME similar to 
that of the original tumor [Silva-Almeida/Ewart].  
 
Besides alterations in metabolism, changes in mitobiogenesis, mitophagy, mitochondrial fusion 
and fission also impact on tumor development and progression. Very often, specific alterations 
in oncogene or onco-suppressor genes affect mitochondrial functions. For instance, wild-type 
TP53 induces mitobiogenesis and promotes OXPHOS, while mutated TP53 up-regulates the 
glycolytic flux in cancer cells. By contrast, if present at germline level, mutated TP53 increases 
the mitochondrial functions, by upregulating the Mitochondrial Transcription Factor A 
(TFAM), the Complex IV component Cyto-chrome c Oxidase 2 (SCO2) and the Citrate carrier, 
which is important for TCA fueling. On the basis of these findings, the use of mitochondrial 
metabolism inhibitors may be considered an adjuvant treatment option in TP53-mutated 
patients [Blandino/Di Agostino]. Also Rel-A, a component of NF-kB, impacts on 
mitochondrial metabolism in a TP53-dependent way. Indeed, in cancer cells with wild-type 
TP53, Rel-A is maintained outside the mitochondria where it up-regulates an OXPHOS-
oriented metabolism. In mutated TP53-cells, Rel-A translocates to mitochondria where it turns 
off the efficient OXPHOS, while the anaerobic glycolysis and the generation of lactate. Lactate 
is taken up by CAFs where if activates NF-kB- and HIF-1α-dependent pro-survival and 
invasive programs. NF-kB also affects mitochondria dynamics, exploiting multiple feed-
forward loops. On the one hand, NF-kB activity promotes mitochondria fission and reduces 
mitochondrial energetic efficiency; on the other hand, ROS generated by inefficient 
mitochondria activate NF-kB, maintaining high the rate of mitochondrial fission. Therein, NF-
kB inhibitors are promising alterative to mitochondrial metabolism inhibitors in reducing 
oncogenesis and invasion [Capece/Zazzeroni].  
Multiple molecular circuitries also link mitochondrial metabolism and autophagy, because 
mitochondria are both inducers or targets of authophagy. Metabolites such α-ketoglutarate, 
FAO products, mitochondrial ROS, as well as phospholipids and ion channels localized in the 
Mitochondria-Associated endoplasmic reticulum (ER) Membrane (MAM), promote the 
assembly of the autophagic machinery. By removing damaged mitochondria and recycling 
metabolic precursors, mitophagy is a driving force in promoting cell survival and resistance to 
exogenous stressors in several cancers. Targeting K+ and Ca++ channels of MAM has been 
proposed as a novel anti-cancer strategy, able to induce Ca++-dependent mitochondrial 
derangement, autophagy alteration and cell death [Ferro/Brisson]. An impaired coupling 
between OXPHOS and ATP synthesis, an increased production of mitochondrial ROS, an 
increased burden of unfolded mitochondrial proteins, all trigger mitophagy and semescence. 
TP53 appears once again to dictate the linkage between mitochondrial metabolism and 
senescence: perturbations of mitochondrial energy metabolism activate p53/p21-dependent 
pathways inducing senescence and limiting mitophagy by preventing the recruitment of Parkin 
1, while TP53-mutated tumors less frequently enter into a senescent phenotype notwithstanding 
the presence of damaged mitochondria [Abate/Caraglia]. 
 
Given their high plasticity, mitochondria are critical in the process of adaptation to stressors, 
leading to cell transformation and/or tumor growth notwithstanding unfavorable conditions. 
For instance, environmental carcinogens such as tobacco-derived nitrosamines, determine a 
metabolic reprogramming that induce irreversible damages and cell death, or cell survival and 
transformation. The activation of mitochondrial metabolism and anti-oxidant enzymes are 
critical in tipping the balance towards nitrosamine-induced tumorigenesis [Rossignol…da 
rivedere con la versione rivista]. 
ER stress is another condition often experimented by solid tumors exposed to hypoxia, nutrient 
deprivation, radiotherapy or chemotherapy. Cells surviving ER stress mount an adaptive 
response in MAM compartment, maintaining a mitochondria-ER coupling that allows the 
mitochondrial inward flux of Ca++. Such moderate increase in Ca++ stimulates OXPHOS and 
ATP synthesis, buffers the ROS levels, and activates an anti-apoptotic response mediated by 
Bcl-2 members. Ca++ releasing channels are controlled by the activation of K-RAS, Akt/mTOR 
pathways and/or by mutations in PTEN, suggesting that alterations in oncogenic or onco-
suppressor genes mediate these metabolic adaptation and pro-survival response during ER 
stress [Rimessi/Pinton].  
Anticancer drugs are among the main stressors that cancer cells must deal with. Mitochondria 
have a key role in promoting the survival to chemotherapy and targeted therapies, 
consequentially determining a drug resistant phenotype. For instance, doxorubicin efficacy is 
drastically reduced in cells with an active mitochondrial metabolism, able to produce huge 
amounts of ATP that fuels the drug efflux transporters belonging to the ATP Binding Cassette 
(ABC) transporters. Of note, cells equipped with both active mitochondrial metabolism and 
cytosolic glycid-catabolyzing pathways (namely glycolysis and pentose phosphate pathway, 
PPP) are even more resistant to doxorubicin. Besides providing ATP, functioning mitochondria 
characterized by efficient OXPHOS flux limit the production of mitochondrial ROS. Since part 
of doxorubicin toxicity is due to the increase of ROS above “harmful” thresholds, the efficient 
oxygen consumption within the mitochondria may prevent such increases in ROS levels. In 
parallel, the efficient production of reductive equivalents such as NADPH and GSH via the 
PPP, further prevents the raise in intracellular ROS levels, contributing to drug resistance 
[Capeloa/Sonveaux]. A mitochondrial metabolic reprogramming is also crucial in the response 
to BRAF inhibitors. Active BRAF promotes anaerobic glycolysis, but melanoma cells exposed 
to Vemurafenib gradually increase the TCA-/OXPHOS-based metabolism and mitobiogenesis. 
A higher mitochondrial metabolism must be sustained by an adequate supply of enzymes and 
cofactors, such as NAD+. Intriguingly, the metabolic shift  induced by Vemrafenib is associated 
with the overexpression of nicotinamide phosphoribosyltransferase (NAMPT), the limiting 
enzyme in NAD+ biosynthesis, that is promoted by BRAF oncogenic signaling and is 
associated with increased cell proliferation, migration and Vemurafenib resistance. Since 
NAMPT is a druggable enzyme, NAMPT inhibitors can be considered as indirect blockers of 
mitochondrial metabolism. By doing so, they may limit tumor progression and drug resistance 
[Audrito/Deaglio]. 
The metabolic symbiosis between tumor and TME cells is an important factor determining 
drug resistance. For instance, the active fueling of TCA cycle of cancer cells with the lactate 
produced by CAFs has been associated to chemoresistance, because it expands a population of 
dormant and drug-resistant cells characterized by a high OXPHOS-based metabolism. 
Mitochondrial inhibitors may eradicate dormant populations and restore chemosensitivity 
[Linden/Corbet]. Although we are moving towards a strongly personalized treatment in the 
oncological research, a lot of efforts are also put in drug repurposing. With their multifaceted 
metabolism and functions, mitochondria are the targets of several FDA-approved drugs, 
including the antidiabetic drug metformin, the antimicrobial drugs atovaquone, 
chloramphenicol, doxycycline, itraconazole and ivermectin, that inhibit OXPHOS and ATP 
synthesis. In parallel, several mitochondrial effects of chemotherapeutic drugs originally 
designed to hit other targets, such as doxorubicin, cisplatin and tamoxifene, have recently 
emerged. The first clinical trials using association of mitochondria-targeting/repurposed drugs 
and chemotherapy have produced encouraging results [Aminzadeh-Gohari/Kofler], paving the 
way to new possible combination treatments for oncological patients.  
Far from being neglected organelles in tumors, mitochondria should be considered versatile 
mediators and therapeutic targets in cancer initiation, progression and resistance. In this 
perspective, we believe that studies on mitochondria will receive a predominant attention in 
the field of cancer cell biology in the next future.   
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